Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

CFR Falls in Chile After Posting Profit Below Estimates

Don't Miss Out —
Follow us on:

March 15 (Bloomberg) -- CFR Pharmaceuticals SA, Chile’s largest drug developer, fell the most in five months after reporting fourth-quarter earnings that were below some analysts’ expectations.

CFR retreated 1.8 percent to 125.01 pesos at the close of trading in Santiago, its steepest decline since Sept. 21. The country’s benchmark Ipsa index lost 0.9 percent.

The pharmaceuticals producer, which has operations in 18 countries including Thailand and Vietnam, said in a statement yesterday that earnings before interest, tax, depreciation and amortization rose 38 percent to $35.8 million. According to calculations by Banco de Chile, Ebitda was $25.7 million, below the bank’s projection of $27.6 million.

“The lower Ebitda was due to higher sales and management costs related to merger and acquisitions activity,” according to the Banco de Chile report. “We can’t rule out downward pressure on the stock.”

To contact the reporter on this story: Eduardo Thomson in Santiago at

To contact the editor responsible for this story: David Papadopoulos at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.